depatuxizumab mafodotin

Home
Ligands
depatuxizumab mafodotin

GtoPdb Ligand ID: 7970

Synonyms: ABT-414

Comment: Depatuxizumab mafodotin (ABT-414) is an antibody-drug conjugate (ADC), which targets a unique tumour-specific EGFR epitope in some cancer cells [5]. The antibody portion recognises EGFR in glioblastoma cells with EGFR gene amplification or expressing the truncated Δ2-7 EGFR mutant (aka EGFRvIII) [2-3]. The antibody is linked to the cytotoxic agent, monomethyl auristatin F (MMAF; PubChem CID 56841603) (information derived from Phillips et al. (2013) [4] and Abbvie's webpage for oncology pipeline compounds and references therein [1].

No information available.

No information available.

Summary of Clinical Use
Clinical trial NCT01741727 (Phase 2) is underway assessing the effectiveness of ABT-414 in advanced solid tumours likely to over-express the EGFR. NCT0180069 (Phase 1) is evaluating the safety and pharmacokinetics of ABT-414 in patients with glioblastoma multiforme.

Summary of Clinical Use

Clinical trial NCT01741727 (Phase 2) is underway assessing the effectiveness of ABT-414 in advanced solid tumours likely to over-express the EGFR. NCT0180069 (Phase 1) is evaluating the safety and pharmacokinetics of ABT-414 in patients with glioblastoma multiforme.

Mechanism Of Action and Pharmacodynamic Effects
ABT-414 binds a unique epitope of EGFR which inaccessible when EGFR is expressed at physiological levels. The epitope becomes accessible in tumours that express Δ2-7 EGFR and in tumors with wild-type amplified EGFR or excessive wild-type EGFR activation [3].

Mechanism Of Action and Pharmacodynamic Effects

ABT-414 binds a unique epitope of EGFR which inaccessible when EGFR is expressed at physiological levels. The epitope becomes accessible in tumours that express Δ2-7 EGFR and in tumors with wild-type amplified EGFR or excessive wild-type EGFR activation [3].